Paediatric cancer hospital St. Jude Children's Research Hospital reported on Monday that it intends to develop a USD412m 625,000-square-foot advanced cancer research centre at its campus.
Slated to break ground in spring 2018 and open in 2021, the advanced research centre is a major component of the company's USD1bn capital expansion plans. The new centre will house cutting-edge technologies and resources that can transform science and accelerate the pace of discovery. The exploration and discovery centre will cultivate transformative research and collaboration and attract scientists and clinicians.
The company's new advanced research centre will treat childhood cancer and other life-threatening diseases. The interactive and interdisciplinary environment is designed specifically for generating new ideas and teamwork. Its labs and spaces will enable researchers to collaborate openly and across departments.
In addition, the company's new advanced research centre will feature state-of-the-art labs focusing on immunology, neurobiology, cell and molecular biology, gene editing, metabolomics, advanced microscopy, epigenetics, genomics, immunotherapy as well as RNA biology.
Developed by The Crump Firm, lead architect on the project and Jacobs Engineering, experts in lab design, the advanced research center propels St. Jude for the long term, accommodating growth for the next 20 years and beyond, with two of eight floors slated for future expansion and evolving technology.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis